Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,225

Document Document Title
WO/2022/206730A8
A new compound which effectively inhibits MAT2A, and which is a compound represented by formula III, or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound represented by formula III, w...  
WO/2024/022365A1
The present invention relates to a Wnt pathway inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inf...  
WO/2024/008097A1
A compound represented by formula (I) or an isomer, a pharmaceutically acceptable salt, a hydrate, a solvate, or a prodrug thereof. The compound is a PROTAC molecule having excellent degradation activity on a CDK protein kinase, lays a s...  
WO/2024/006879A1
Provided herein are inhibitors of ubiquitin-specific-processing Protease 1 (USP1), their pharmaceutical compositions, and methods of use for treating diseases or disorders, such as cancers described herein.  
WO/2023/215367A1
Provided herein are compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Z1, Z2, Z3, R1, R2, R3, and n are as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a comp...  
WO/2023/143501A1
Provided are a compound possessing the structure of formula (I) and having excellent Wnt pathway inhibitory activity, or a pharmaceutically acceptable salt, an isotope derivative, or a stereoisomer thereof. Further provided are a prepara...  
WO/2023/126297A1
The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combi...  
WO/2023/078426A1
Provided in the present invention are a compound, a pharmaceutical composition containing same, and the use thereof. The compound interferes with the interaction between the menin protein and MLL1 or MLL2 or a MLL fusion oncoprotein, and...  
WO/2023/061437A1
The present invention relates to a salt of an antitumor drug and a crystal form thereof, and specifically relates to a pharmaceutical salt of the compound N-(3-(2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)- 7-oxo-6-phenyl-8(7H)-...  
WO/2023/059583A1
The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDK1, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC ...  
WO/2023/046114A1
Disclosed in the present invention is a compound as represented by formula I or a pharmaceutically acceptable salt thereof. Such compounds exhibit an excellent effect of targeted inhibition of non-canonical mutations of EGFR and have a g...  
WO/2023/028054A1
Described herein are inhibitors of EGFR exon 20 insertion mutants and methods of treating cancer comprising the administration of said inhibitors.  
WO/2023/028022A1
A method of synthesizing a pharmacological compound substance by attaching a psychoactive base substance to an amino acid and creating a prodrug with modified pharmacological behavior. A prodrug made by the method. A pharmaceutical compo...  
WO/2023/016134A1
A compound of general formula (I) containing a tetrahydropterin structure, and a preparation method therefor and a use thereof. A composition containing the compound of general formula (I) or a pharmaceutically acceptable salt thereof an...  
WO/2023/005894A1
An inhibitor compound as represented by formula (I) for a Wnt pathway and a pharmaceutical composition containing same, and the use of the compound as represented by the formula (I) for preventing and/or treating cancers, tumors, inflamm...  
WO/2023/284747A1
The present application discloses a novel use of an EGFR inhibitor. The EGFR inhibitor is a compound N-(3-(2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)- 7-oxo-6-phenyl-8(7H)-pteridyl)phenyl)acrylamide, which may be used in the p...  
WO/2022/268180A1
Provided is a compound as represented by formula (I), or a prodrug, a tautomer, a stereoisomer, a solvate, an isotope derivative, or a pharmaceutically acceptable salt thereof. The compound has a relatively strong MAT2A inhibitory effect...  
WO/2022/272307A1
The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface receptor, such as a folate receptor. The cell surface folate binding compound can trigger the receptor to internaliz...  
WO/2022/272313A1
Small molecules compounds and methods of their synthesis are provided. Small molecules identified can inhibit histone acetyltransferase 1 activty. Formulations and medicaments are also provided that are directed to the treatment of human...  
WO/2022/268167A1
The present invention relates to a medicine for treating xerophthalmia and a method for improving wearing experience of people with contact lens discomfort, and further relates to a therapeutic eye drop.  
WO/2022/261770A1
The present invention relates to a combination comprising a neurotensin receptor binding compound and FOLFIRINOX for use for the treatment of a neurotensin receptor overexpressing tumour in a subject.  
WO/2022/260545A1
The subject of the invention is a new methotrexate-glucose conjugate derivative, its synthesis, and its use in the treatment and prevention of neoplasms, preferably in the treatment and prevention of neoplasms selected from: skin cancer,...  
WO/2022/236272A2
The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of ...  
WO/2022/206730A1
A new compound which effectively inhibits MAT2A, and which is a compound represented by formula III, or a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug of the compound represented by formula III: ,...  
WO/2022/194166A1
The use of a methotrexate analogue in the treatment of an inflammatory skin disease. The methotrexate analogue not only has a strong activity and low toxicity and low side effects, but can also target skin in a distributed manner so as t...  
WO/2022/175222A1
The present invention relates to cryptophycin compounds, to new cryptophycin payloads, to new cryptophycin conjugates, to compositions containing them and to their therapeutic use, especially as anticancer agents.  
WO/2022/096015A1
A method for preparing a 3,6-diaminopyrazine-2,5-dicarboxylic acid and a synthetic intermediate thereof. The method comprises the step of preparing pyrimido[4,5-g]pteridine-2,4,7,9 (1H,3H,6H,8H)-tetrone or a disalt (pteridine) thereof fr...  
WO/2022/008419A1
The present invention relates to novel antifolate linker-drugs, conjugates comprising such antifolate linker-drugs, and the use thereof in the treatment of diseases, such as cancer, autoimmune and infectious diseases, optionally in combi...  
WO/2021/261062A1
Provided is an aqueous solution having, dissolved therein, 0.3 to 200 mM of a stilbene compound (A) that is a compound represented by formula (1) or a glycoside thereof and 0.3 to 200 mM of a flavin derivative (B) selected from riboflavi...  
WO/2021/249558A1
The present invention relates to a pteridone derivative as an RSK protein kinase inhibitor and an application thereof. Specifically, the present invention relates to a compound represented by formula I, a pharmaceutical composition compr...  
WO/2021/244555A1
Disclosed are a compound intermediate material for synthesizing a chiral drug and a preparation method for the compound intermediate material. The intermediate for synthesis disclosed in the present invention has a low production cost, s...  
WO/2021/221097A1
Provided are: a novel compound, and a pharmaceutically acceptable salt thereof, represented by formula (1), the compound having a histamine H4 receptor-regulating effect and being useful in the treatment and/or prevention of an illness o...  
WO/2021/203673A1
The present application provides a nitrogen containing compound, an organic electroluminescent device using same, and an electronic device. A chemical structure of an organic compound in the present invention comprises a carbazole ring. ...  
WO/2021/163727A1
The present invention relates to compounds useful as inhibitors of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as well as their use for treating diseases and disorders associated with PIKfyve.  
WO/2021/133144A1
The present invention relates to: a novel organic electron transfer mediator which shows an excellent oxidation-reduction potential; and a device comprising same, such as an electrochemical biosensor, which has improved performance.  
WO/2021/123116A1
The present invention relates to a compound represented by the following formula (I): A[B-(C)v]w, wherein A is a photoprotective moiety, B is a linker, C is a functional group, v is an integer from 1 to 2000, and w is an integer from 1 t...  
WO/2021/112661A1
The present invention relates to a process for obtaining polymer nanoparticles stabilised with a non-ionic polymer surfactant functionalised with a ligand, for receptor-mediated drug delivery. The distinctive feature of the invention is ...  
WO/2021/072269A1
The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can b...  
WO/2020/239953A1
The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3 (hereinafter P2X3 inhibitors); particularly the invention relates to compounds that are pyridopyrimidines derivatives, methods of preparing such compou...  
WO/2020/201724A1
The disclosure provides a tracer composition. The composition comprises a fluorescent molecule which fluoresces when exposed to an excitation wavelength, and thereby emit a photon with a wavelength between 400 and 600 nm; and a gelling a...  
WO/2020/172664A1
Described herein are genetic recognition reagents that bind specifically to a target nucleic acid and comprise terminal left-handed PNA cooperative binding domains that enable concatenation of two or more of the recognition reagents when...  
WO/2020/156017A1
The present invention relates to a compound represented by formula (I) or a tautomer, optical isomer, deuterated substance, oxynitride, solvate, pharmaceutically acceptable salt or prodrug thereof, a preparation method for the compound, ...  
WO/2020/156437A1
The present invention discloses an AKT inhibitor, and specifically relates to a compound represented by formula I or a pharmaceutically acceptable salt thereof. The present invention further provides a preparation method thereof, and the...  
WO/2020/142612A1
Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmace...  
WO/2020/140055A1
Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are u...  
WO/2020/089443A1
The invention relates to crystalline folate salts. The salt consists of a folate anion and an organic cation. The folate anion is 5-methyl-(6S)-tetrahydrofolic acid, and the cation is an organic compound which is an alkanolamine selected...  
WO/2020/092375A1
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes...  
WO/2020/083089A1
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a polymorph, a tautomer, an isotope compound, and a metabolite or a prodrug thereof for treating diseases that ...  
WO/2020/078455A1
The present invention relates to a structurally novel TLR8 (Toll-like receptor 8) agonist and, in particular, to a compound thereof of formula (I), a pharmaceutically acceptable salt and an isomer thereof.  
WO/2020/073906A1
Disclosed is a kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also disclosed are a pharmaceutical composition comprising the kinase inhi...  

Matches 1 - 50 out of 1,225